Mylan 21,15 € +2,27% ,GrB
Anzeige
Meldung des Tages: Der nächste Gold-Hebel? 200 Meter Treffer, volle Kassen – warum diese Aktie jetzt auffällt
Neuester,
zuletzt geles. Beitrag
Antworten | Hot-Stocks-Forum Übersicht
Zurück
Weiter
... 6 7 8 9 11 12 13 14 ...
Antworten | Hot-Stocks-Forum Übersicht
Zurück
Weiter ... 6 7 8 9 11 12 13 14 ...
Citigroup - Mylan "buy"
Beiträge:
463
Zugriffe: 92.371 / Heute: 1
Zugriffe: 92.371 / Heute: 1
|
Werbung
Entdecke die beliebtesten ETFs von SPDR
328.911 sind bereits durch ,buran und danke und weitermachen
Handelsplatz Geld-Stk. Geld Geld-Brief Brief Brief-Stk. Spread Zeit
Tradegate 300 20,88 € 21,13 € 300 1,20% 10:36:16
Berlin 300 20,88 € 21,13 € 300 1,20% 10:36:16
Düsseldorf 0 20,87 € 21,145 € 0 1,32% 10:36:19
Frankfurt 480 20,868 € 21,144 € 473 1,32% 10:36:16
München 200 20,865 € 21,145 € 200 1,34% 10:36:16
Stuttgart 1.000 20,70 € 21,215 € 1.000 2,49% 10:31:39
Nasdaq 400 27,21 $ 30,55 $ 200 12,27% 10:02:01
GrB
Tradegate 300 20,88 € 21,13 € 300 1,20% 10:36:16
Berlin 300 20,88 € 21,13 € 300 1,20% 10:36:16
Düsseldorf 0 20,87 € 21,145 € 0 1,32% 10:36:19
Frankfurt 480 20,868 € 21,144 € 473 1,32% 10:36:16
München 200 20,865 € 21,145 € 200 1,34% 10:36:16
Stuttgart 1.000 20,70 € 21,215 € 1.000 2,49% 10:31:39
Nasdaq 400 27,21 $ 30,55 $ 200 12,27% 10:02:01
GrB
Kaufpreis 28,49 $ ..600 shares ..spread 2,04%
Handelsplatz Geld-Stk. Geld Geld-Brief Brief Brief-Stk. Spread Zeit
Tradegate 300 20,85 € 21,09 € 300 1,15% 11:20:59
Berlin 300 20,88 € 21,12 € 300 1,15% 11:05:59
Frankfurt 480 20,866 € 21,13 € 474 1,27% 11:07:59
Düsseldorf 0 20,865 € 21,13 € 0 1,27% 11:08:02
München 200 20,865 € 21,13 € 200 1,27% 11:05:59
Stuttgart 1.000 20,66 € 21,175 € 1.000 2,49% 10:56:40
Nasdaq 200 27,21 $ 28,45 $ 100 4,56% 11:08:02
GrB
Tradegate 300 20,85 € 21,09 € 300 1,15% 11:20:59
Berlin 300 20,88 € 21,12 € 300 1,15% 11:05:59
Frankfurt 480 20,866 € 21,13 € 474 1,27% 11:07:59
Düsseldorf 0 20,865 € 21,13 € 0 1,27% 11:08:02
München 200 20,865 € 21,13 € 200 1,27% 11:05:59
Stuttgart 1.000 20,66 € 21,175 € 1.000 2,49% 10:56:40
Nasdaq 200 27,21 $ 28,45 $ 100 4,56% 11:08:02
GrB
2.926.516 shares unter'm Ticker geschmissen und bedient
Datum Erster Hoch Tief Schluss Stücke Volumen
22.01.13 27,97 28,00 27,74 27,89 $ 3.906.444 107 M
GrB
22.01.13 27,97 28,00 27,74 27,89 $ 3.906.444 107 M
GrB
bei nem starken Volumen von 81,6 M ..Schluss in zart rosa ..geht voll klar
Datum Erster Hoch Tief Schluss Stücke Volumen
29.01.13 28,25 28,385 28,11 28,29 $ 3.998.319 105 M
GrB
29.01.13 28,25 28,385 28,11 28,29 $ 3.998.319 105 M
GrB
gutes Blatt
Datum Erster Hoch Tief Schluss Stücke Volumen
30.01.13 28,26 28,42 28,12 28,20 $ 4.323.323 114 M
thread Pott +188,46%
Datum Erster Hoch Tief Schluss Stücke Volumen
30.01.13 28,26 28,42 28,12 28,20 $ 4.323.323 114 M
thread Pott +188,46%
Datum Erster Hoch Tief Schluss Stücke Volumen
31.01.13 28,15 28,40 28,06 28,27 $ 6.128.407 172 M
31.01.13 28,15 28,40 28,06 28,27 $ 6.128.407 172 M
ask:: Preis:: 31,21 $ shares:: 200 spread:: 8,71% / buran
1.769.977 shares getickert .. 29,04 in Dollar waren bereits zu sehen / buran
ohne Makel und Einwände
Schlusswerte::28,86 $ +0,20% +0,06 $ In Euro: 21,594 € | Nasdaq buran
Schlusswerte::28,86 $ +0,20% +0,06 $ In Euro: 21,594 € | Nasdaq buran
Mylan 21,66 € +0,77%
__________________
undddd Abfahrt ,buran
__________________
undddd Abfahrt ,buran
Mylan Launches Generic Version of Xopenex® Inhalation Solution16:05 18.03.13
PR Newswire
PITTSBURGH, March 18, 2013
PITTSBURGH, March 18, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Specialty L.P. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Levalbuterol Inhalation Solution USP, 0.31 mg/3 mL (0.0103%), 0.63 mg/3 mL (0.021%), and 1.25 mg/3 mL (0.042%), (Concentrate). This product is the generic version of Sunovion's Xopenex® Inhalation Solution, which is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease.
Levalbuterol Inhalation Solution USP, 0.31 mg/3 mL, 0.63 mg/3 mL, and 1.25 mg/3 mL, had U.S. sales of approximately $438.8 million for the 12 months ending Dec. 31, 2012, according to IMS Health. Mylan has begun shipping this product.
Currently, Mylan has 182 ANDAs pending FDA approval representing $80 billion in annual sales, according to IMS Health. Thirty-six of these pending ANDAs are potential first-to-file opportunities, representing $21.1 billion in annual brand sales, for the 12 months ending June 30, 2012, according to IMS Health.
Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of approximately 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com
SOURCE Mylan Inc.
Quelle: PR Newswire
GrB
PR Newswire
PITTSBURGH, March 18, 2013
PITTSBURGH, March 18, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Specialty L.P. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Levalbuterol Inhalation Solution USP, 0.31 mg/3 mL (0.0103%), 0.63 mg/3 mL (0.021%), and 1.25 mg/3 mL (0.042%), (Concentrate). This product is the generic version of Sunovion's Xopenex® Inhalation Solution, which is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease.
Levalbuterol Inhalation Solution USP, 0.31 mg/3 mL, 0.63 mg/3 mL, and 1.25 mg/3 mL, had U.S. sales of approximately $438.8 million for the 12 months ending Dec. 31, 2012, according to IMS Health. Mylan has begun shipping this product.
Currently, Mylan has 182 ANDAs pending FDA approval representing $80 billion in annual sales, according to IMS Health. Thirty-six of these pending ANDAs are potential first-to-file opportunities, representing $21.1 billion in annual brand sales, for the 12 months ending June 30, 2012, according to IMS Health.
Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of approximately 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com
SOURCE Mylan Inc.
Quelle: PR Newswire
GrB
Bucheinsicht:
Zeit Kurs Stück
11:29:10 22,615 € 15
MfG b.
Zeit Kurs Stück
11:29:10 22,615 € 15
MfG b.
Es gibt keine neuen Beiträge.
|
Neueste Beiträge aus dem Mylan Forum
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
5 | 462 | Citigroup - Mylan "buy" | buran | buran | 25.04.21 01:35 | |
| 2 | Pfizer und Mylan erwägen Fusion bei patentfreiem A | JKHA | 29.07.19 10:02 |